Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES

FAST MONEY FEATURES

PollFast Money PollsFAST MONEY POLL
Get in the post game.  Respond to our
"Question of the Day" right now.


52 Week High52 Week High TRADER RADAR
Which stock should be on your screen? Follow the clues to solve this puzzle.



Trade SchoolTRADE SCHOOL
Grab a pencil because school is in session and the Fast Money traders are teaching class.


FAST MONEY EMERGING MONEY
EMERGING MONEY TOP 20
Fast Money's index for the world.




PodcastFM PodcastsFAST MONEY PODCASTS
Download Fast Money onto your MP3 Player.




FM WIDGETFAST MONEY WIDGET
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.



ShopSHOP FOR FAST MONEY MERCHANDISE
Get your game on with Fast Money gear.




Wanna See Our PhotosFAST MONEY PHOTOS!
Check out our scrapbook.  These "pix" are guaranteed winners.




SignupNewsletterNEWSLETTER
Sign up and receive a recap email every Friday after the show!





FM Mobile AlertFAST MONEY MOBILE ALERTS
Get advanced information about the next Fast Money.



Fast Money HomeFast Money Rapid RecapAbout Fast MoneyFast Money BiosFast Money Web ExtraFast Money Disclaimer
Font size:
Jan.10
6:36 PM ET
Thursday, 10 Jan 2008
DNA's Test

Genentech kicks off biotech earnings season Monday after the bell. Will higher sales of Avastin and Herceptin drive shares?

CNBC Pharmaceuticals reporter Mike Huckman joins the panel for this conversation. Following is a summary of his main points.


Analysts expect Genentech [DNA  Loading...      ()   ] to report sales of $616 million says Huckman, and it’s widely believed the stock will move on sales and not earnings, he says.

Also, it’s worth noting that Genentech has shared its cancer drug Rituxan with Biogen Idec [BIIB  Loading...      ()   ].

Meanwhile, Biogen Idec is awaiting a big decision that may come as soon as Friday or Monday from the FDA on Tysabri, a drug for Crohn's disease. It could move the stock. It’s worth noting, Tysabri is shared with Elan [ELN  Loading...      ()   ], as well as PDL BioPharma [PDLI  Loading...      ()   ] which receives a small royalty.

Also, it’s worth noting that, historically at the end of the JPMorgan Conference some stocks roll over. In other words, a sell-off occurs. Investors buy into these companies and then realize the drugs won’t hit the market for 6-18 months.

I think it will be an eventful year adds Pete Najarian. I expect to see M&A in this space.

______________________________________________________
Got something to say? Send us an e-mail at and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to .

Trader disclosure: On Jan 10, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (YHOO); Najarian Owns (AMR), (BIIB), (C), (MSFT), (EBAY); Najarian Owns (CFC) Options, (WM) Options,(YHOO) Options; Finerman's Firm Owns (KSS), (WMT), (YHOO), (AEO); Finerman's Firm Owns (MDY) Puts And Is Short (MDY); Finerman's Firm Owns (MSFT) Options; Finerman's Firm Is Short (IJR), (IYR), (SPG); Finerman's Firm Is Short (LEH) And Owns (LEH) Puts; Finerman's Firm Owns Russell 2000 Puts And Is Short (IWM); Finerman's Firm Owns S&P 500 Puts And Is Short (SPY)

© 2008 CNBC.com

Permalink: /id/22592859

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis